Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats

Pharmaceutical Research

Volumn 21, Issue 8, 2004, Pages 1413-1418

  Karpf, Ditte M ^a   Holm, René ^b   Kristensen, Henning G ^a   Müllertz, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

Cremophor RH40; dispersion; halofantrine; lecithin; lymphatic transport

Indexed keywords

CREMOPHOR; HALOFANTRINE; PHOSPHATIDYLCHOLINE; SURFACTANT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CANNULATION; CONCENTRATION RESPONSE; CONSCIOUSNESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG METABOLISM; DRUG TRANSPORT; INTERMETHOD COMPARISON; LYMPHATIC SYSTEM; MICROEMULSION; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; EMULSIONS; INJECTIONS, INTRAVENOUS; INTESTINES; LYMPH; LYMPHATIC SYSTEM; MALE; PHENANTHRENES; PHOSPHATIDYLCHOLINES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS; TRIGLYCERIDES;

EID: 4344702625     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000036915.03725.19     Document Type: Article

References (29)

1. W. N. Charman. Lipid Vehicle and formulation effects on intestinal lymphatic drug transport. In W. N. Charman and V. J. Stella (eds), Lymphatic Transport of Drugs, CRC Press, Boca Raton, 1992, pp. 113-180.
2. W. N. Charman and V. J. Stella. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 34:175-178 (1986).
3. C. M. O'Driscoll. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15:405-415 (2002).
4. C. J. H. Porter and W. N. Charman. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50:61-80 (2001).
5. P. Tso and J. A. Balint. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am. J. Physiol. 250:G715-G726 (1986).
6. R. Holm, A. Müllertz, E. Christensen, C. E. Høy, and H. G. Kristensen. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci. 14:331-337 (2001).
7. T. Ichihashi, H. Kinoshita, Y. Takagishi, and H. Yamada. Effect of bile on absorption of mepitiostane by the lymphatic system in rats. J. Pharm. Pharmacol 44:565-569 (1992).
8. C. J. H. Porter, S. A. Charman, and W. N. Charman. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J. Pharm. Sci. 85:351-356 (1996).
9. C. J. H. Porter, S. A. Charman, A. J. Humberstone, and W. N. Charman. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J. Pharm. Sci. 85:357-361 (1996).
10. D. J. Hauss, S. E. Fogal, J. V. Ficorilli, C. A. Price, T. Roy, A. A. Jayaraj, and J. J. Keirns. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 87:164-169 (1998).
11. S. B. Clark. Chylomicron composition during duodenal triglyceride and lecithin infusion. Am. J. Physiol. 235:E183-E190 (1978).
12. C. M. Mansbach, A. Arnold, and M. A. Cox. Factors influencing triacylglycerol delivery into mesenteric lymph. Am. J. Physiol. 249:G642-G648 (1985).
13. G. Cornaire, J. F. Woodley, S. Saivin, J. Y. Legendre, S. Decourt, A. Cloarec, and G. Houin. Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 50:576-579 (2000).
14. J. L. Bollman, J. C. Cain, and J. H. Grindlay. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J. Lab. Clin. Med. 33:1349-1352 (1948).
15. R. Holm, A. Müllertz, G. P. Pedersen, and H. G. Kristensen. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. Pharm. Res. 18:1299-1304 (2001).
16. A. J. Humberstone, G. J. Currie, C. H. Porter, M. J. Scanlon, and W. N. Charman. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. J. Pharm. Biomed. Anal. 13:265-272 (1995).
17. P. Kan, Z. B. Chen, C. J. Lee, and I. M. Chu. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J. Control. Rel. 58:271-278 (1999).
18. K. M. Park, M. K. Lee, K. J. Hwang, and C. K. Kim. Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Int. J. Pharm. 183:145-154 (1999).
19. M. L. Go and S. S. Feng. Halofantrine-phospholipid interactions: monolayer studies. Chem. Pharm. Bull. (Tokyo) 49:871-876 (2001).
20. T. Porsgaard and C. E. Høy. Lymphatic transport in rats of several dietary fats differing in fatty acid profile and triacylglycerol structure. J. Nutr. 130:1619-1624 (2000).
21. B. Davies and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
22. P. Tso, K. L. Buch, J. A. Balint, and J. B. Rodgers. Maximal lymphatic triglyceride transport rate from the rat small intestine. Am. J. Physiol. 242:G408-G415 (1982).
23. M. M. Hussain. A proposed model for the assembly of chylomicrons. Atherosclerosis 148:1-15 (2000).
24. B. D. Tarr and S. H. Yalkowsky. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm. Res. 6:40-43 (1989).
25. F. J. Field and S. N. Mathur. Intestinal lipoprotein synthesis and secretion. Prog. Lipid Res. 34:185-198 (1995).
26. D. M. Woodcock, M. E. Linsenmeyer, G. Chojnowski, A. B. Kriegler, V. Nink, L. K. Webster, and W. H. Sawyer. Reversal of multidrug resistance by surfactants. Br. J. Cancer 66:62-68 (1992).
27. S. M. Khoo, J. H. Porter, G. A. Edwards, and W. N. Charman. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J. Pharm. Sci. 87:1538-1541 (1998).
28. W. N. Charman and V. J. Stella. Effect of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int. J. Pharm. 33:165-172 (1986).
29. J. M. Laher, M. W. Rigler, R. D. Vetter, J. A. Barrowman, and J. S. Patton. Similar bioavailability and lymphatic transport of benzo(a)pyrene when administered to rats in different amounts of dietary fat. J. Lipid Res. 25:1337-1342 (1984).